UCFA
RVNC

United Capital Financial Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

United Capital Financial Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,193
Closed -$26.2K – 1094
2024
Q2 		$26.2K Buy
+10,193
New +$34.8K ﹤0.01% 1024

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

United Capital Financial Advisors's RVNC Position: Q3 2024 in Review

United Capital Financial Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 10,193 shares — an estimated $26.2K sold.

United Capital Financial Advisors first reported a position in RVNC in Q2 2024 and held it in 1 quarter. The position peaked at $26.2K in Q2 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • United Capital Financial Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • United Capital Financial Advisors sold 10,193 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $26.2K.
  • United Capital Financial Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 1 quarter.
  • United Capital Financial Advisors's Revance Therapeutics, Inc. position peaked at $26.2K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on United Capital Financial Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.